ZKB Reads Tysabri Recommendation To Serono
newratings.com - USA
0748 GMT [Dow Jones] An FDA panel recommends that Biogen's (BIIB) and Elan's (ELN) drug Tysabri returns to market. Although this ...
See all stories on this topic

Tysabri news is good for ISEQ
Ireland Online - Dublin,Ireland
Elan soared €2.40 (21.2%) to €13.70 following news that multiple sclerosis drug Tysabri is expected to be approved to go back on sale shortly. ...
See all stories on this topic

Tysabri's Fate Set to Be Determined
TheStreet.com - USA
Regulators are set to consider in the next two days whether Tysabri, the multiple sclerosis drug fromBiogen Idec (BIIB:Nasdaq - commentary - research ...

Serono's Main Threat Isn't Tysabri -Lombard
newratings.com - USA
0915 GMT [Dow Jones]--Serono's (SRA) Rebif sales are likely to see only minimal impact from the near-certain return of Tysabri to market, says Lombard Odier ...

Teva Still Looks Promising Despite Renewed Tysabri Threat
Forbes - USA
The research firm said it has factored into its Teva (nasdaq: TEVA - news - people ) model the expectations that Tysabri will get the go-ahead to return to the ...

Questions remain over Tysabri - US FDA
RTE.ie - Ireland
It is unclear whether Elan and Biogen Idec's multiple sclerosis drug Tysabri may raise the risk of a rare, life-threatening brain infection when used alone, US ...

Wall St set to extend rally on easing rate worries
Financial Times - London,England,UK
... Drugmakers Biogen and Elan also advanced after their Tysabri multiple sclerosis drug was approved by the US Food and Drug Administration advisory panel. ...
See all stories on this topic

Stocks may rise on BOJ's policy move
BusinessWeek - USA
... Of companies in focus, Biogen Idec looked set to soar after it and Elan's Tysabri multiple sclerosis drug won the approval of a Food and Drug Administration ...
See all stories on this topic

Schering Not Seen Hit By Return Of Tysabri
newratings.com - USA
... Dow Jones] HVB keeps Schering (SHR) at underperform, with a EUR59 target after an FDA panel recommended approval of Biogen and Elan's Tysabri for relapsing ...

Elan makes gains on ISEQ
Ireland Online - Dublin,Ireland
Pharmaceutical company Elan saw its stock rise by over 15% following the announcement that it's multiple sclerosis drug Tysabri is expected to be put back on ...
See all stories on this topic

Biogen Idec's Tysabri Seen Exceeding Expectations
Forbes - USA
RBC Capital Markets upgraded shares of Biogen Idec to "outperform" from "neutral" after an advisory panel unanimously recommended Tysabri return to the market. ...
See all stories on this topic

Tysabri Focus Obscures Another Biogen Idec Advance
International News Service - Sydney,Australia
... But the Cambridge company is concerned that the focus on Tysabri is taking attention away from another one of its products, Rituxan. ...

FDA panel to weigh benefits, risks of Tysabri
MarketWatch - USA
... Drug Administration will ask an outside panel of medical experts this week to make recommendations about whether the multiple sclerosis drug Tysabri should be ...